Abhaya Kumar, managing director of Shasun Pharmaceuticals expects the company's topline to grow 40-50% in FY12. He told CNBC-TV18 in an interview that their confirmed orders for third and fourth quarter are very strong.
The bigger concern for the company is funds availability for future projects than reducing debt on the books. However, Kumar expects to bring down debt from Rs 320 crore to Rs 220-210 crore in FY12. Here is the edited transcript of his interview. Also watch the accompanying video. Q: What is the quantum of debt on the company
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
